These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17002476)

  • 1. The generalisability of pharmacoeconomic studies: issues and challenges ahead.
    Mason JM; Mason AR
    Pharmacoeconomics; 2006; 24(10):937-45. PubMed ID: 17002476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The generalisability of pharmacoeconomic studies.
    Mason J
    Pharmacoeconomics; 1997 Jun; 11(6):503-14. PubMed ID: 10168092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do international pharmacoeconomic guidelines say about economic data transferability?
    Barbieri M; Drummond M; Rutten F; Cook J; Glick HA; Lis J; Reed SD; Sculpher M; Severens JL;
    Value Health; 2010 Dec; 13(8):1028-37. PubMed ID: 20667054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?
    Sculpher MJ; Drummond MF
    Pharmacoeconomics; 2006; 24(11):1087-99. PubMed ID: 17067194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative review of the pharmacoeconomic guidelines in South Africa.
    Carapinha JL
    J Med Econ; 2017 Jan; 20(1):37-44. PubMed ID: 27564849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines.
    Ramaekers BL; Joore MA; Grutters JP
    Value Health; 2013; 16(5):855-62. PubMed ID: 23947981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt.
    Elsisi GH; Kaló Z; Eldessouki R; Elmahdawy MD; Saad A; Ragab S; Elshalakani AM; Abaza S
    Value Health Reg Issues; 2013; 2(2):319-327. PubMed ID: 29702884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
    Knies S; Severens JL; Ament AJ; Evers SM
    Value Health; 2010 Aug; 13(5):519-27. PubMed ID: 20712601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying priority technical and context-specific issues in improving the conduct, reporting and use of health economic evaluation in low- and middle-income countries.
    Luz A; Santatiwongchai B; Pattanaphesaj J; Teerawattananon Y
    Health Res Policy Syst; 2018 Feb; 16(1):4. PubMed ID: 29402314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.
    Molnar FJ; Dalziel WB
    Drugs Aging; 1997 Mar; 10(3):219-33. PubMed ID: 9108895
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.